Traditional Chinese medicine composition for treating hypertension and preparation method thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating hypertension and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hypertension is prepared from dracocephalum moldavica, leontopodium leontopodum, uncaria, corn stigma and Chinese dates. The traditional Chinese medicine composition is simple in medicine flavor, clear in medicine effect and capable of relaxing blood vessels and effectively reducing the blood pressure value of hypertensive rats, and all the medicines act together to promote hypertension treatment. The composition disclosed by the invention takes effect quickly and has an exact effect when being used for treating hypertension, and has a good clinical application prospect.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for treating hypertension and a preparation method thereof. Background Art

[0002] Hypertension is a cardiovascular syndrome with elevated systemic arterial pressure as its main clinical manifestation, and is one of the most important risk factors for cardiovascular and cerebrovascular diseases. Calcium ion antagonists, diuretics and other antihypertensive drugs are often used in clinical intervention, but these drugs have problems such as unstable blood pressure control and large blood pressure variability, and patients are prone to many adverse reactions such as palpitations, headaches, ankle edema, etc.

[0003] In recent years, more and more clinical evidence shows that Chinese medicine can effectively lower blood pressure. In the treatment of hypertension, in addition to lowering blood pressure, it can also improve symptoms and reduce complications. However, there are many medicinal flavors in the treatment of hypertension with Chinese medicine at present, and the curative effect is not ideal and cannot achieve long-term blood pressure lowering effect, the treatment time is long, and it is easy to relapse. For example, Chinese patent application CN201611224120.5 discloses a Chinese medicine composition for treating hypertension, which is mainly composed of 10-20 parts of rhubarb, 10-20 parts of Polygonum multiflorum, 15-30 parts of Polygonum cuspidatum, 20-40 parts of Astragalus, 20-40 parts of Angelica sinensis, 10-30 parts of Uncaria rhynchophylla, 15-25 parts of Polygonatum sibiricum, 20-30 parts of Prunella vulgaris, 3-8 parts of chrysanthemum, 10-20 parts of white peony root, 15-40 parts of Semen Cassiae, 15-30 parts of honeysuckle, 10-20 parts of plantain, 10-20 parts of hawthorn, and 10-20 parts of motherwort. The invention claims that it starts with the recovery mechanism and blood pressure regulation mechanism, so that the self-regulation disorder of vascular activity can be gradually eliminated and its function can be restored to normal, thereby eliminating the original cause of high blood pressure and curing hypertension; however, the invention has many raw materials and the mechanism of action is not clear. At the same time, too many raw materials not only bring burdens to the user, but long-term use may also cause other side effects. Summary of the invention

[0004] Therefore, based on the above background and in view of the shortcomings of the prior art, the present invention provides a Chinese medicine composition for treating hypertension and a preparation method thereof, which has a simple and reasonable formula, a high utilization rate of medicinal materials and no toxic side effects, and a blood pressure lowering effect that can reach that of ordinary chemical first-line blood pressure lowering drugs.

[0005] The technical solution provided by the present invention is:

[0006] A Chinese medicine composition for treating hypertension, comprising the following raw materials:

[0007] 10-15 parts of fragrant blue orchid, 3-12 parts of Uncaria rhynchophylla, 3-6 parts of edelweiss, 15-30 parts of corn silk and 6-15 parts of jujube.

[0008] Preferably, it is composed of the following raw materials: 15 parts of fragrant blue orchid, 5 parts of edelweiss, 12 parts of Uncaria rhynchophylla, 30 parts of corn silk and 15 parts of jujube.

[0009] Based on the same inventive concept, the present invention applies the Chinese medicine composition to the preparation of medicines for treating hypertension.

[0010] Furthermore, the drug is in oral dosage form.

[0011] Furthermore, the oral dosage forms include mixtures, teas, granules, tablets, capsules, pills and solutions.

[0012] Furthermore, the medicine uses the Chinese medicine composition or an extract or an extract prepared using the Chinese medicine composition as a raw material as an active ingredient.

[0013] Furthermore, the extract is prepared by the following method: extracting the Chinese medicine composition with a solvent to obtain the extract;

[0014] The extract is prepared by the following method: extracting the Chinese medicine composition with a solvent to obtain an extract; concentrating and drying the extract to obtain the extract;

[0015] The solvent is water, alcohol or an aqueous solution of alcohol.

[0016] Based on the same inventive concept, the present invention also provides a method for preparing a drug for treating hypertension, which is prepared using the Chinese medicine composition as a raw material.

[0017] Further, the following steps are included:

[0018] Weigh the raw materials according to the weight portion, add 8 to 12 times the amount of water, soak for 15 to 45 minutes, decoct for 1 to 3 times, each time for 30 to 90 minutes, combine the decoctions, filter, and concentrate the decoctions under reduced pressure at 60 to 80° C. to a medicinal solution with a crude drug concentration of 3.3 g / mL.

[0019] Furthermore, the decoction is performed twice.

[0020] Furthermore, the reduced pressure concentration temperature is 70°C.

[0021] The above technical solution has the following beneficial effects:

[0022] The present invention combines the theory of traditional Chinese medicine, and the effects of each medicinal flavor are as follows:

[0023] The herb grows mostly in arid hills, rocky riverbanks and valleys. It has a wide range of applications, mainly for the treatment of angina pectoris, coronary heart disease, hypertension, atherosclerosis, asthma, etc. Its main chemical components include flavonoids and phenolic substances, which can inhibit the proliferation and migration of vascular smooth muscle cells, enhance cholesterol outflow, dilate blood vessels, and resist atherosclerosis by regulating the TNF-α / NF-κB pathway.

[0024] Leontopodium, which mainly grows in areas above 2,000 meters above sea level, is a plateau medicinal plant with a slightly bitter taste and cold nature. It has the effects of clearing heat, detoxifying and stopping bleeding. Modern pharmacological research shows that the main components of Leontopodium are flavonoids, phenylpropanoids, phenolic acids and terpenes, which have the effects of protecting the cardiovascular system, anti-oxidation and lowering blood sugar.

[0025] Uncaria rhynchophylla is sweet in taste and cool in nature. It has the effects of calming wind and relieving convulsions, clearing away heat and calming the liver. It is often used for internal liver wind movement, high fever convulsions, headache and dizziness, etc. It is the main raw material of many famous Chinese patent medicines such as Uncaria rhynchophylla tablets, Zhengtian pills, and Tianma Uncaria rhynchophylla granules, and a common medicine in Chinese medicine formulas. Modern pharmacological studies have shown that Uncaria rhynchophylla mainly contains alkaloids, triterpenes, phenols, flavonoids, quinones and other ingredients, which have the effects of lowering blood pressure, resisting oxidative stress, and resisting cerebral ischemia-reperfusion injury, and mainly acts on the cardiovascular and central nervous systems.

[0026] Corn silk is sweet and cool in nature. It has the effects of promoting diuresis and removing dampness, promoting bile secretion and relieving jaundice. It is often used for hypertension, diabetes, jaundice, etc. Modern pharmacological studies have shown that corn silk contains a variety of chemical components such as polysaccharides, flavonoids, phenols, amino acids, etc., which can prevent and treat cardiovascular diseases (regulating blood lipids, lowering blood pressure, and lowering blood sugar) through mechanisms such as anti-oxidative stress, anti-inflammation, protecting vascular endothelium, and regulating coagulation function.

[0027] Jujube, sweet in taste and warm in nature, has the effects of nourishing the middle qi, nourishing blood and calming the mind. It is often used for spleen deficiency, poor appetite, fatigue and loose stools, and irritability in women. Jujube is a food and medicine product, containing glycosides, polyphenols, flavonoids, triterpene acids and other chemical components. Pharmacological studies have shown that jujube has the activities of nourishing blood, anti-coagulation, antioxidant, anti-inflammatory, and protecting nerves.

[0028] Hypertension has fire syndrome (in the early and middle stages, with liver yang hyperactivity and liver fire inflammation as its core), fluid syndrome (in the middle and late stages, with dampness and turbidity in the body and difficulty in urination), and deficiency syndrome (in the late stage, due to long-term use of antihypertensive drugs, the spleen and stomach will be damaged, leading to spleen deficiency and dampness). Most doctors in the past dynasties and modern scholars emphasize that "all wind dizziness belongs to the liver" and advocate the treatment from the perspective of liver wind and liver yang. In the process of hypertension disease progression, its etiology and pathogenesis are transformed from simple fire syndrome and excess syndrome to deficiency and excess mixed syndrome. The present invention combines the basic theory of traditional Chinese medicine and adopts scientific compatibility, wherein Xiangqinglan dispels wind and heat, cools the liver and stops bleeding, regulates the cardiovascular system, improves its function, and is matched with Uncaria rhynchophylla to calm the wind and calm the nerves, clears heat and calms the liver, and dilates blood vessels. The two are used together to enhance the effect of soothing liver yang and reducing liver fire, improve the antihypertensive effect, and promote the recovery of the balance of qi, blood, yin and yang in the body, which is the main medicine. At the same time, Xiangqinglan is warm in nature, while Uncaria rhynchophylla is slightly cold in nature. The medicinal properties of the two are mutually restricted, and the compatibility is used to balance the medicinal properties and improve the safety of medication. Leontopodium can promote diuresis and eliminate dampness, remove turbidity and reduce fat, promote urination, clear dampness and heat, and can relieve edema in the body, so it is a ministerial drug. Corn silk can clear heat and promote diuresis, promote bile secretion and reduce jaundice, and assist in removing lingering phlegm and dampness, so it is an adjuvant drug. Jujube can nourish the middle and replenish qi, nourish blood and calm the mind, nourish the spleen and stomach, and replenish qi and blood, so it is a guiding drug. The combination of these drugs can calm the liver and suppress yang, promote diuresis and clear heat, and nourish the spleen and eliminate dampness, achieving the overall effect of lowering blood pressure.

[0029] Compared with the prior art, the present invention has the following beneficial effects: compared with the existing commonly used chemical drugs and Chinese medicine prescriptions, the present invention has a simple and reasonable taste, mild medicinal properties, high medicinal material utilization rate, and clear efficacy. It regulates the body through multiple components, multiple targets, and multiple levels without toxic side effects, and is suitable for long-term use. Animal pharmacodynamic studies have shown that the Chinese medicine prescription can significantly reduce the systolic and diastolic blood pressure of hypertension model animals, and the drugs work together to promote hypertension treatment, with significant and lasting antihypertensive effects. DETAILED DESCRIPTION

[0030] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Example 1: A Chinese medicine composition for treating hypertension, which is composed of the following raw materials:

[0032] 15 parts of Rhizoma Cibotii, 5 parts of Herba Edelweiss, 12 parts of Rhizoma Uncariae, 30 parts of Stigma Maydis and 15 parts of jujubes.

[0033] The following are drugs for treating hypertension in different oral dosage forms prepared using the Chinese medicine composition of Example 1 as raw materials.

[0034] ①Combination dosage form:

[0035] The preparation method is as follows:

[0036] (1) Weigh 10 times the amount of water, add 10 times the amount of water, and soak for 30 minutes;

[0037] (2) Decoction twice, each time for 1 h, combine the decoctions, and filter;

[0038] (3) The mixture was concentrated under reduced pressure at 70°C to a medicinal solution having a crude drug concentration of 3.3 g / mL.

[0039] ②Tea dosage form:

[0040] The preparation method is as follows:

[0041] (1) Weigh and dry the cymbidium, edelweiss, Uncaria rhynchophylla, corn silk and jujube;

[0042] (2) Mix well and put into tea bag.

[0043] ③ Granule dosage form

[0044] The preparation method is as follows:

[0045] (1) Weigh 10 times the amount of water, add 10 times the amount of water, and soak for 30 minutes;

[0046] (2) Decoction twice, each time for 1 h, combine the decoctions, and filter;

[0047] (3) Concentrating under reduced pressure at 70°C to a specific gravity of about 1.09 (65±5°C) to obtain a clear paste;

[0048] (4) passing the clear paste through a 100-mesh sieve and then spray drying to obtain dry extract powder;

[0049] (5) sieving, mixing, and dry granulation to obtain the product.

[0050] ④Tablet dosage form

[0051] The preparation method is as follows:

[0052] (1) Weigh 10 times the amount of water, add 10 times the amount of water, and soak for 30 minutes;

[0053] (2) Decoction twice, each time for 1 h, combine the decoctions, and filter;

[0054] (3) Concentrating under reduced pressure at 70°C to a specific gravity of about 1.09 (65±5°C) to obtain a clear paste;

[0055] (4) passing the clear paste through a 100-mesh sieve and then spray drying to obtain dry extract powder;

[0056] (5) Screening, mixing, dry granulation, adding a carrier or / and an excipient, and tableting.

[0057] Example 2: Pharmacological Experiment of the Present Invention

[0058] 1. Reagents

[0059] Irbesartan (Lot: S27F8D30066, purity: ≥98%, Shanghai Yuanye Biotechnology Co., Ltd.), sodium carboxymethyl cellulose (Lot: JS280468, CP, viscosity 300-800, Shanghai Yuanye Biotechnology Co., Ltd.), angiotensin II (Lot: H2318189, purity: 90%, Shanghai Aladdin Biochemical Technology Co., Ltd.), sodium chloride injection (Lot: E23072927, Chenxin Pharmaceutical Co., Ltd.), chloral hydrate (Lot: 20240702, Qingdao Yulong Seaweed Co., Ltd.).

[0060] 2. Instruments

[0061] Metlab-1D single-channel rat non-invasive blood pressure measuring instrument (Nanjing Calvin Biotechnology Co., Ltd.); RE-3000AA rotary evaporator (Shanghai Yarong Biochemical Instrument Factory); LC-UC-150 ultrasonic cleaning machine (Shanghai Lichen Bangxi Instrument Technology Co., Ltd.); XS205DU one-hundred-thousandth electronic balance (Mettler-Toledo Co., Ltd.)

[0062] 3. Drug solution to be tested

[0063] (1) The Chinese medicine composition of the present invention: weigh 15 parts of Herba Lysimachiae, 5 parts of Leontopodium glutamate, 12 parts of Uncaria rhynchophylla, 30 parts of Stigma corni and 15 parts of jujube, add 10 times the amount of water, soak for 30 minutes, decoct twice, each time for 1 hour, combine the decoctions, filter, and concentrate under reduced pressure at 70°C to a medicinal solution with a crude drug concentration of 3.3 g / mL.

[0064] The following is the source information of the liquid medicine raw materials:

[0065] Uncaria rhynchophylla origin: Guangxi; batch number: 240625; manufacturer: Suzhou Chunhuitang Pharmaceutical Co., Ltd.;

[0066] Origin of Edelweiss: Inner Mongolia; Batch No.: 240814; Manufacturer: Suzhou Tianling Chinese Medicine Pieces Co., Ltd.

[0067] Corn silk origin: Jiangsu; batch number: 240720; manufacturer: Suzhou Tianling Chinese Medicine Pieces Co., Ltd.;

[0068] Jujube origin: Shandong; batch number: 240715; manufacturer: Suzhou Tianling Chinese Medicine Pieces Co., Ltd.;

[0069] Xiangqinglan Origin: Xinjiang; Batch No.: 240814; Manufacturer: Suzhou Tianling Chinese Medicine Pieces Co., Ltd.;

[0070] (2) Preparation of irbesartan suspension: irbesartan was finely ground in a mortar, and 0.5% sodium carboxymethylcellulose solution was used as a suspending agent to prepare an irbesartan suspension with a concentration of 1.35 mg / mL for later use.

[0071] 4. Animal grouping and modeling

[0072] (1) Experimental materials: 40 healthy male 6-week-old SPF Sprague Dawley (SD) rats weighing 190-210 g were purchased from Shanghai Bikai Biotechnology Co., Ltd., license number: SCXK (Shanghai) 2023-0009. They were allowed to eat and drink freely, and the indoor temperature was controlled at (22±2)°C and the humidity was (50±10)%.

[0073] After 1 week of adaptive feeding, 40 mice were randomly divided into 4 groups: blank control group (fed with ordinary feed), model control group, positive control group, and combination group, with 10 mice in each group.

[0074] The model control group, positive control group, and combination group were respectively injected subcutaneously with angiotensin II (Ang II) combined with a high-salt diet to induce hypertension models;

[0075] The construction process is as follows:

[0076] Rats were injected subcutaneously with 0.2 mL of 10-7 mol / L Ang II (prepared in physiological saline) at the head and neck and were allowed to freely consume a high-salt diet containing 8% NaCl.

[0077] Mice in the blank control group were only injected with the same volume (0.2 mL) of normal saline and were allowed to eat normal feed freely once a day.

[0078] The intervention time for all rats was 2 weeks.

[0079] (2) Construction results: After the rats in each group were treated in a ventilated, constant temperature and quiet environment for 2 weeks, their tail artery blood pressure was measured using the Metlab-1D single-channel rat non-invasive blood pressure system. The rats in a conscious state were placed in a non-invasive blood pressure incubator and the temperature was adjusted to 34°C. Then the airbag cuff and sensor were put on the rat's tail and covered with a transparent lid. After the rat was in a calm state and a sawtooth pulse appeared at the baseline, the rat's tail was inflated and pressurized. The software system was used to analyze and record the rat's systolic blood pressure, diastolic blood pressure, and mean arterial pressure. Repeat 3 times and take the average value. The systolic blood pressure of the rats after 2 weeks was >20 mmHg compared with that before injection, which was considered a successful model.

[0080] (3) Drug administration results test in rats

[0081] After successful modeling, each group of rats was given corresponding drug treatment, wherein the rats in the composition group were given the medicinal solution prepared by the Chinese medicine composition of Example 1, at 0.21 mL / 100 g (about 6.9 g / kg) body weight by gavage, once a day; the rats in the positive control group were given 13.5 mg / kg of irbesartan, at 1.0 mL / 100 g body weight by gavage, once a day, for 4 consecutive weeks.

[0082] Rats in the blank control group and model control group were given purified water by gavage at 0.21 mL / 100 g.

[0083] The dosage of the composition was calculated based on the body surface area conversion coefficient between adults and rats, which was equivalent to 1 times the clinical dosage for adults. During the administration period, except for the blank control group rats, the rats in other groups continued to be injected with Ang II and freely consumed high-salt feed. After administration, the rats were measured once a week (every 7 days), and the experimental process was completed by the same person in the same time period.

[0084] The experimental data were processed by EXCEL software, and the results were analyzed by t test for inter-group test. The statistical results were tested with α = 0.05 as the test limit, where P ≤ 0.05 indicated statistical significance, and P ≤ 0.01 indicated that the difference tested was very significant.

[0085] (4) Experimental results

[0086] ①Effect on systolic blood pressure in hypertensive rats

[0087] Before administration, the systolic blood pressure of rats in other groups was close to no significant difference and was significantly higher than that of the blank control group. Compared with the blank control group, the systolic blood pressure of rats in the model control group continued to increase, and the difference was statistically significant (P < 0.01). Compared with the model group, the systolic blood pressure of the positive drug control group was significantly reduced after continuous administration for 1-4 weeks (P < 0.01), and the systolic blood pressure of the combination group was significantly reduced after 1-4 weeks of administration (P < 0.01). Compared with the positive control group, there was no significant difference in the effect of the combination group on reducing systolic blood pressure at each detection time point for 1-4 weeks of administration.

[0088] The above experiments show that the Chinese medicine composition of the present invention has the effect of significantly reducing the systolic blood pressure of rats, which is equivalent to the systolic blood pressure reducing effect of the positive control drug irbesartan group. The results are shown in Table 1.

[0089] Table 1: Systolic blood pressure of rats in each group after continuous administration for 4 weeks (±s, mmHg, n=10)

[0090] Group dose Week 0 Week 1 Week 2 Week 3 Week 4 Blank control group \ 103.5±0.4 105.5±3.6 107.6±4.2 107.5±1.9 106.9±2.4 Model control group \ <![CDATA[141.7±4.5 ** ]]> <![CDATA[142.1±6.7 ** ]]> <![CDATA[144.5±7.1 ** ]]> <![CDATA[146.8±3.3 ** ]]> <![CDATA[147.3±3.5 ** ]]> Positive control group 0.21mL / 100g <![CDATA[147.6±2.1 ** ]]> <![CDATA[135.7±7.8 ** ]]> <![CDATA[130.2±8.7 *# ]]> <![CDATA[127.8±7.4 *# ]]> <![CDATA[123.8±14.7 # ]]> Combination group 6.9g / kg <![CDATA[153.2±9.8 ** ]]> <![CDATA[149.9±7.8 ** ]]> <![CDATA[134.3±5.2 ** ]]> <![CDATA[126.2±3.4 *# ]]> <![CDATA[120.6±6.9 # ]]>

[0091] Note: Compared with the blank control group: *P<0.05, ** P<0.01; compared with the model control group: # P<0.05, ## P<0.01.

[0092] ②Effects on diastolic blood pressure in hypertensive rats

[0093] Compared with the blank control group, the diastolic blood pressure of the rats in the model control group continued to increase, and the difference was statistically significant (P < 0.01). Compared with the model control group, the diastolic blood pressure of the positive control group was significantly reduced (P < 0.01 or P < 0.05); the diastolic blood pressure of the combination group was significantly reduced after 1-4 weeks of administration (P < 0.01). Compared with the positive drug irbesartan group, there was no significant difference in the effect of the combination group on reducing diastolic blood pressure after 1-4 weeks of administration.

[0094] The above results show that the Chinese medicine composition of the present invention has the effect of significantly reducing the diastolic blood pressure of rats, which is equivalent to the diastolic blood pressure reducing effect of the positive control drug irbesartan group. The results are shown in Table 2.

[0095] Table 2 Diastolic blood pressure of rats in each group after continuous administration for 4 weeks (±s, mmHg, n=10)

[0096] Group dose Week 0 Week 1 Week 2 Week 3 Week 4 Blank control group \ 90.9±7.3 93.4±6.3 93.8±8.0 94.2±3.3 95.1±1.4 Model control group \ <![CDATA[128.5±2.3 ** ]]> <![CDATA[130.1±6.1 ** ]]> <![CDATA[133.3±5.8 ** ]]> <![CDATA[136.0±5.9 ** ]]> <![CDATA[136.1±2.2 * ]]> Positive control group 0.21mL / 100g <![CDATA[130.9±3.7 ** ]]> <![CDATA[117.0±5.3 ** ]]> <![CDATA[112.4±6.7 * ]]> 107.5±8.5 104.6±13.9 Combination group 6.9g / kg <![CDATA[131.5±10.1 **## ]]> <![CDATA[116.6±8.5 ** ]]> <![CDATA[110.6±5.3 * ]]> 106.6±0.2 104.1±8.4

[0097] Note: Compared with the normal control group: * P<0.05, ** P<0.01; compared with the model control group: # P<0.05, ## P<0.01.

[0098] It can be seen from the above pharmacological tests that the composition has a good antihypertensive effect equivalent to that of chemical drugs and can significantly reduce the systolic and diastolic blood pressure of hypertensive rats.

[0099] The present invention and its implementation methods are described above, and such description is not restrictive, and the actual methods are not limited thereto. In short, if ordinary technicians in the field are inspired by it, without departing from the purpose of the invention, they can design implementation methods and embodiments similar to the technical solution without creativity, which should all fall within the protection scope of the present invention.

Claims

1. A Chinese medicine composition for treating hypertension, characterized in that: It is composed of the following raw materials: 10-15 parts of fragrant blue orchid, 3-12 parts of Uncaria rhynchophylla, 3-6 parts of edelweiss, 15-30 parts of corn silk and 6-15 parts of jujube.

2. The Chinese medicine composition for treating hypertension according to claim 1, characterized in that: The invention is composed of the following raw materials: 15 parts of hyacinthus annuus, 5 parts of leontopodium alpinum, 12 parts of uncaria, 30 parts of corn silk and 15 parts of jujube.

3. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a drug for treating hypertension.

4. The use according to claim 3, characterized in that: The drug is in oral dosage form.

5. The use according to claim 4, characterized in that: The oral dosage forms include mixtures, teas, granules, tablets, capsules, pills and solutions.

6. The use according to any one of claims 3 to 5, characterized in that: The medicine uses the Chinese medicine composition according to claim 1 or 2 or an extract or an extract prepared using the Chinese medicine composition as a raw material as an effective ingredient.

7. The use according to claim 6, characterized in that: The extract is prepared by the following method: extracting the Chinese medicine composition according to claim 1 or 2 with a solvent to obtain the extract; The extract is prepared by the following method: extracting the Chinese medicine composition according to claim 1 or 2 with a solvent to obtain an extract; concentrating and drying the extract to obtain the extract; The solvent is water, alcohol or an aqueous solution of alcohol.

8. A method for preparing a drug for treating hypertension, characterized in that: The method is prepared using the Chinese medicine composition according to claim 1 or 2 as raw material.

9. The method for preparing a drug for treating hypertension according to claim 8, characterized in that: The steps include: Weigh the raw materials according to the weight portion, add 8 to 12 times the amount of water, soak for 15 to 45 minutes, decoct for 1 to 3 times, each time for 30 to 90 minutes, combine the decoctions, filter, and concentrate the decoctions under reduced pressure at 60 to 80° C. to a medicinal solution with a crude drug concentration of 3.3 g / mL.

10. The method for preparing a drug for treating hypertension according to claim 9, characterized in that: Decoction times are 2 times.